ObsEva SA OTC Markets

Equities

OBSEF

CH1260041939

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:24 2024-04-18 pm EDT			5-day change	1st Jan Change
0.005 ^USD	0.00%		0.00%	-85.71%

Apr. 03	ObsEva to Delist from the SIX Swiss Exchange	MT
Mar. 20	ObsEva SA Announces to Wind-Down the Operations	CI

Obseva Sa Announces Resignation of Current Chief Financial Officer David Renas, Effective January 5, 2022

October 29, 2021 at 04:30 pm EDT

ObsEva SA announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022. ObsEva has retained an executive search firm to assist the Company?s Board of Directors with identifying a new Chief Financial Officer.

Latest news about ObsEva SA

ObsEva to Delist from the SIX Swiss Exchange	Apr. 03	MT
ObsEva SA Announces to Wind-Down the Operations	Mar. 19	CI
ObsEva SA Announces Catarina Edfjäll to Step Down from the Board	Mar. 19	CI
ObsEva to Wind Down, Flags SIX Swiss Delisting	Feb. 28	MT
ObsEva Secures Temporary Moratorium Against Creditors	Jan. 31	MT
ObsEva to File for Moratorium in Geneva, Switzerland	Nov. 30	MT
ObsEva to Return Global Rights on Ebopiprant to Xoma	23-10-30	MT
ObsEva Net Loss Narrows in H1	23-09-27	MT
ObsEva SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
ObsEva Terminates Licensing Deal with Yuyuan BioScience for Oral Oxytocin Receptor	23-07-13	MT
ObsEva SA Announces Termination of Its Sub-Licensing Agreement with Yuyuan Bioscience	23-07-13	CI
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Switzerland's ObsEva Appoints Permanent CEO	23-05-02	MT
ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.	22-12-07	CI

Chart ObsEva SA

Duration

Period

More charts

Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat womenâs reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs